Company news

IXICO PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Result of GM, Issue of Equity & TVR

October 25, 2024

Correction of clerical error

October 22, 2024

Director/PDMR Shareholding

October 16, 2024

Result of Retail Offer

October 15, 2024

Exercise of Options & Director/PDMR Purchase

October 10, 2024

Result of Placing and Subscription

October 9, 2024

Retail Offer

October 8, 2024

Placing and Subscription

October 8, 2024

Board Appointment

August 5, 2024

Further progress in HD consortium

July 29, 2024

IXICO to support on Global Alzheimer's Platform Foundation's Bio-Hermes 2 trial

May 23, 2024

Notice of half year results

May 7, 2024

Life Molecular Imaging – Neuraceq Supply Agreement

April 15, 2024

Imeka Collaboration Agreement

April 3, 2024

Directorate Change

January 12, 2024

Update regarding Nominated Adviser and Broker

December 27, 2023

Change of Auditor

December 15, 2023

Financial Results for year ended 30 September 2023

December 5, 2023

Appointment of Independent Non-Executive Director

October 5, 2023

IXICO: Huntington’s Disease Image Harmonization Consortium secures new member and funding to complete large-scale analysis of brain changes using IXIQ.Ai

July 12, 2023

Half year report

May 23, 2023

Investor Meet Company presentation

May 16, 2023

Extension of Huntington's disease consortium

April 3, 2023

Price Monitoring Extension

January 31, 2023

Second Price Monitoring Extn

January 31, 2023

Total Voting Rights

January 3, 2023

Director Bed & ISA Dealing

December 22, 2022

AGM 2023 – Notice

December 16, 2022

PDMR Exercise of Options

December 13, 2022

Contract Update

December 8, 2022

Financial Results for the year ended 30 Sept 2022

December 7, 2022

HD-IH Consortium

September 21, 2022

Grant of Share Options

September 14, 2022

Trading Update and FY2023 Guidance

September 1, 2022

Contract Win - Replacement

July 26, 2022

Contract Extension

June 14, 2022

Half-year Report and Trading Update

May 24, 2022

Investor Presentation

May 16, 2022

Consortium Agreement in Huntington's Disease

May 10, 2022

New Contract Win

April 21, 2022

Contract worth circa £800k

March 8, 2022

Launch of IXIQ.Ai Deep learning AI-based platform

February 14, 2022

Contract award worth circa £1.0m

February 8, 2022

Appointment of Senior Therapeutic Advisor

January 31, 2022

Dementia collaboration

January 26, 2022

Non-Executive Director Appointment

January 21, 2022

Huntington's disease contract update

January 20, 2022

Grant of share options

January 10, 2022

Financial Results for the year ended 30 Sept 2021

December 7, 2021

Notice of Results

November 22, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.